Auscann

  • Ticker:ASX:AC8
  • Sector:Healthcare
  • Industry:Pharmaceutical
  • CEO:Ido Kanyon
  • Founded:2013
Categories:
About Us

AusCann (ASX:AC8) is undoubtedly one of the most prominent competitors in the Australian medicinal cannabis market.

The company has already acquired the full set of licenses necessary to grow and manufacture cannabis-based medicines and is in the midst of purchasing a new research and development facility in Perth.

The cost of the R&D site will take a $5.25 million bite out of AusCann's $40 million in funding, and represents the latest step in a broader strategy shift. In September last year, the company announced that it would be moving away from the pot-growing sector, and instead pivot towards the development of cannabis-based medicinal products, particularly in capsule format.

The facility will focus on AusCann's cannabinoid pharmaceutical product pipeline, supporting the development of both innovative formulations and dose forms. To achieve this Auscann will be employing a vertically integrated strategy, beginning with cultivation and production, all the way through to the eventual manufacture and distribution of products.

More From Auscann...
Canopy Growth Ups Ownership in AusCann to 13%
Ready, Set, Grow – MediPharm Keeps Pace with Australian Cannabis License
AusCann Gets New CEO: Ido Kanyon
Dynamic Duo – MediPharm Joins Forces with Cronos and Announces Strong Q1 Results
AusCann Makes Shift from Cannabis Farmer to Pill Manufacturer
AusCann on Track to Run Clinical Trials in 2019
3 Australian Cannabis Dispensaries to Watch in 2019
Pot Stocks – Bulls and Bears Week 12
Pot Stocks – Bulls and Bears Week 10
AusCann Group Announces New CEO
Load More Results
Investor Presentation

The latest update from the company

Click Here
Stay updated about
this company

Signup to get updates.

Management
Ido Kanyon
CEO
Ido Kanyon has extensive pharmaceutical and medical device business experience across the life-science value chain. Before being appointed CEO of AusCann, Mr. Kanyon held a broad range of executive positions at Teva Pharmaceuticals, where he oversaw key leadership roles. He holds a B.Sc.(Agr.) from The Hebrew University Of Jerusalem, Israel, an MBA from IE Business School in Spain and Postgraduate training with Mckinsey & Co. Kanyon also holds a fellowship with the College of Physicians of Philadelphia and participates in advisory boards with several technological incubators, such as the leading US accelerator Dreamit Ventures.
Dr. Mal Washer
Chairman
Dr Washer was a Liberal member of the Australian House of Representatives from 1998 to 2013. He was educated at the University of Western Australia, graduating in 1970 with degrees in medicine and surgery. He was a general practitioner before entering politics & established a number of prominent medical centres in Western Australia. Mal was also past chair of the Alcohol and Other Drugs Council of Australia. He has extensive experience in agricultural and horticultural activities and currently operates a commercial avocado plantation in Western Australia bringing highly relevant medical and horticultural expertise and experience to AusCann.
Dr. Marcel Bonn-Miller
Non-Executive Director
Dr. Bonn-Miller is Global Clinical Scientific Director of Spectrum Therapeutics, the medical division of Canopy Growth specialized in the development and commercialization of validated cannabis medicines. Dr. Bonn-Miller is a world-renowned researcher and pharmaceutical executive, bringing over 18 years of extensive clinical research and development expertise in cannabinoid-products for medical use. He has received funding for 27 research grants, has published 140 peer-reviewed academic papers and has led or contributed to 19 clinical trials. Prior to Canopy Growth, Dr. Bonn-Miller was Director of Cannabinoid Research for Zynerba Pharmaceuticals, a leading transdermal cannabinoid pharmaceutical company.
Dr Paul MacLeman
Executive Director
Dr. MacLeman has over 25 years’ board and executive experience across the life sciences, agricultural and not for profit sectors. This includes strategy formulation, capital raising, business development, technology commercialization, and sales & marketing. He has also launched a variety of products in Australia, the US and Asia, founded life sciences start-ups in the biologics area and worked in investment banking. Dr MacLeman is currently Chair of AdAlta Limited, Livac Pty Limited, and is a Non-Executive Director of Sypharma Pty Limited. He Chairs the committee reviewing the National Vocational Education Training Package in Pharmaceuticals and has in the past Chaired the Committee to develop a nationally recognized Course in Pharmaceutical Manufacture for Victoria, the AusBiotech Agricultural Advisory Board and has been Managing Director of Nasdaq, ASX and TSX listed companies.
CHERYL EDWARDES
Independent Non-Executive Director
Cheryl was the former Attorney-General for Western Australia and Minister for the Environment. Cheryl was most recently Executive General Manager for External Affairs, Government Relations and Approvals at Hancock Prospecting-a company associated with one of Australia’s wealthiest individuals. Cheryl has extensive experience of successful negotiations to ensure that critical primary agreements and government approvals are obtained in a timely fashion. Such agreements and approvals include the Roy Hill Rail State Agreement and the Special Railway Licence; Port Lease and Licence; Native Title Agreements; Environmental Approvals, State and Federal; and many other critical approvals for Hancock Prospecting Pty Ltd and Roy Hill Iron Ore and Infrastructure.
Quentin Megson
Chief Operating and Financial Officer
Quentin Megson has over 25 years’ experience in the finance and management sector and holds a Bachelor of Commerce and is a Member of the Australian Institute of Chartered Accountants. He started as a Tax Advisory Manager with a major accounting firm before moving to a medium tier accounting firm as a Partner. He then chose to move into commerce as the CFO and Company Secretary of an ASX listed company operating in the forestry/ agriculture industry and then moved into an operational role as General Manager of Operations & Corporate Services. Quentin has also held non-executive director roles within several companies.